Pelage Pharmaceuticals
Last verified 2026-06-12. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $120.0Mattributed |
|---|---|
| Latest round | series-b, $120.0M, 2025-10-01attributed |
| Founded | 2019 |
| Headquarters | Los Angeles, US |
| Industry | bio |
| Stage | series-b+ |
| Website | pelagepharma.com |
Pelage Pharmaceuticals develops regenerative medicines for hair loss, led by PP405, a topical small molecule that reactivates dormant hair follicle stem cells. It is for people across all hair types, including those with pattern hair loss and chemotherapy-induced alopecia. Based on a UCLA discovery, PP405 targets stem cells directly, not hormones.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-b | $120.0M | undisclosed |
Detected tech stack
doubleclick floodlight, elementor 4.1.1, google analytics, google tag manager, jetengine, jquery 3., jquery migrate 3.4.1, mysql, nginx, php, slick, wordpress 7.0
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | pelagepharma.com, read 2026-06-12 |
| Description | self-reported | pelagepharma.com, read 2026-06-12 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.